eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2016
vol. 67
 
Share:
Share:
abstract:
Original paper

A rare CD5-positive subgroup of diffuse large B-cell lymphoma – clinical, morphological and immunophenotypic features in Polish patients

Nina Woźnialis
1
,
Beata Gierej
1, 2
,
Lidia Popławska
3
,
Mateusz Ziarkiewicz
4
,
Elżbieta Kulczycka
1
,
Bogna Ziarkiewicz-Wróblewska
1, 2

1.
Department of Pathology and Laboratory Diagnostics, Maria Skłodowska-Curie Institute and Oncology Centre, Warsaw, Poland
2.
Department of Pathology, Center for Biostructure Research, Medical University of Warsaw, Warsaw, Poland
3.
Department of Lymphoid Malignancies, Maria Skłodowska-Curie Institute and Oncology Centre, Warsaw, Poland
4.
Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
Pol J Pathol 2016; 67 (3): 235-243
Online publish date: 2016/11/25
View full text Get citation
 
PlumX metrics:
The aim of the study was to assess the incidence of CD5-positive diffuse large B-cell lymphoma (DLBCL) in the Polish population and to describe its morphologic and clinical characteristics. The study included 36 patients with CD5-positive DLBCL, diagnosed and treated in the Maria Skłodowska-Curie Institute and Oncology Centre, Warsaw, Poland and the Medical University of Warsaw, Poland in the years 2002-2013. The control group consisted of 28 patients with CD5-negative DLBCL. CD5-positive DLBCL accounted for 6.26% of all DLBCL cases diagnosed in the Maria Skłodowska-Curie Institute and Oncology Centre in the years 2008-2012. The incidence is comparable to other European countries, lower than noted in Japan and higher than in the US. Patients with CD5-positive DLBCL, in comparison to the CD5-negative group, were characterized by: (1) older age (≥ 60 vs. younger) and worse general status (ECOG ≥ 2 vs. < 2), (2) lower frequency of complete remission (CR), (3) higher expression of unfavorable prognostic factors (BCL2, FOXP1, CD44) and MMP-9, and (4) lower expression of favorable prognostic factors (CD30, cyclin D1, cyclin D3) and TIMP-2.
keywords:

NHL, CD5-positive DLBCL, prognostic factors

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.